By John Q. Hosedrinker 
According to sources, President Donald Trump is expected to issue an executive order that could reclassify marijuana, potentially as early as Monday. This action would shift cannabis companies to different tax regulations and encourage investment. Such a move is anticipated to be a positive development for the cannabis industry, possibly allowing banks to more easily serve the sector. While seen as progress towards normalizing cannabis under national law, experts note that reclassification is a partial victory, and further action, including Congressional involvement, will be needed for broader regulatory changes and reforms.
Read the original article here
Trump expected to sign an executive order to reclassify marijuana as soon as Monday, according to sources cited by CNBC, and it’s certainly creating a buzz in the market, with pot stocks surging in response. It’s almost impossible not to wonder about the motivations behind such a move, especially given the timing. With so many pressing issues like the Epstein case, economic concerns, and expiring Obamacare credits, the immediate question is, “Why now?”
The cynical perspective is that this is simply a political maneuver, a desperate attempt to sway voters. Republicans have historically opposed legalization, and now, suddenly, it’s potentially acceptable. Some think this is a transparent effort to capture votes. The polls must be truly unfavorable for Trump to resort to this tactic. The creation of an edible product line for the Trump family further cements this theory.
However, the implications could be far more complex. Some voices speculate that this could be a stepping stone towards greater control over drugs in general. There’s concern that this might pave the way to criminalizing other medications, potentially affecting vulnerable groups. The timing of such announcements can’t be ignored. There’s a pattern of Trump making small, seemingly odd moves, which then turn out to be bigger power grabs later on.
The question of whether this is truly a move towards legalization or just a reclassification is paramount. Rescheduling to Schedule III, like steroids, is not the same as outright legalization, which would treat marijuana like alcohol. The difference is significant. One reduces penalties, while the other ends federal prohibition entirely and it will not rectify any of the issues that face the industry.
The political dynamics involved are also striking. The Democrats’ hesitance on legalization has provided an opening for Trump to take credit. If this executive order goes ahead, some are worried it may be viewed as a deflection from more serious problems.
Regardless of the intent, a lot of people see this as a distraction, a way to shift focus away from other pressing issues. This perspective is a common thread running through the reactions to the news.
Then, there’s the economic aspect, with hopes that rescheduling could help the industry with banking and taxes, but again, that’s not the same as full legalization. The surge in pot stocks is a direct result of these hopes, but many are cautious, anticipating a classic “pump and dump” scenario.
Critics argue that this move, regardless of the impact, is a half-measure. The lack of true legalization could result in a disappointment. Some commentators feel this will not fix the financial problems facing Americans. Some question the ethics behind such a decision and wonder what the ultimate goal is.
The impact of this executive order, if signed, is yet to be fully understood. Will it lead to full legalization, or is it merely a political stunt designed to shift focus? Or is it part of a larger plan to control or criminalize other drugs? The uncertainty has made investors and observers remain vigilant.